NZ609501A - Antibodies to notum pectinacetylesterase - Google Patents
Antibodies to notum pectinacetylesteraseInfo
- Publication number
- NZ609501A NZ609501A NZ609501A NZ60950111A NZ609501A NZ 609501 A NZ609501 A NZ 609501A NZ 609501 A NZ609501 A NZ 609501A NZ 60950111 A NZ60950111 A NZ 60950111A NZ 609501 A NZ609501 A NZ 609501A
- Authority
- NZ
- New Zealand
- Prior art keywords
- notum
- activity
- antibodies
- antibody
- vitro
- Prior art date
Links
- 102000004251 pectinacetylesterase Human genes 0.000 title 1
- 108010072638 pectinacetylesterase Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 3
- 238000003556 assay Methods 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 2
- OWCBHUCUQCCZTM-UHFFFAOYSA-K 8-octanoyloxypyrene-1,3,6-trisulfonate Chemical compound C1=C2C(OC(=O)CCCCCCC)=CC(S([O-])(=O)=O)=C(C=C3)C2=C2C3=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C2=C1 OWCBHUCUQCCZTM-UHFFFAOYSA-K 0.000 abstract 1
- 101000604110 Homo sapiens Palmitoleoyl-protein carboxylesterase NOTUM Proteins 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- RZVSWISDVXUSGY-UHFFFAOYSA-K trisodium;8-octanoyloxypyrene-1,3,6-trisulfonate Chemical compound [Na+].[Na+].[Na+].C1=C2C(OC(=O)CCCCCCC)=CC(S([O-])(=O)=O)=C(C=C3)C2=C2C3=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C2=C1 RZVSWISDVXUSGY-UHFFFAOYSA-K 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41692710P | 2010-11-24 | 2010-11-24 | |
| PCT/US2011/061785 WO2012071381A1 (en) | 2010-11-24 | 2011-11-22 | Antibodies to notum pectinacetylesterase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ609501A true NZ609501A (en) | 2014-12-24 |
Family
ID=46146184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ609501A NZ609501A (en) | 2010-11-24 | 2011-11-22 | Antibodies to notum pectinacetylesterase |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20130302346A1 (enExample) |
| EP (1) | EP2643019B1 (enExample) |
| JP (1) | JP6033229B2 (enExample) |
| KR (2) | KR20180069083A (enExample) |
| CN (1) | CN103298490B (enExample) |
| AU (1) | AU2011332007C1 (enExample) |
| BR (1) | BR112013012858B1 (enExample) |
| CA (1) | CA2817415C (enExample) |
| CO (1) | CO6721048A2 (enExample) |
| DK (1) | DK2643019T3 (enExample) |
| ES (1) | ES2718849T3 (enExample) |
| HU (1) | HUE043576T2 (enExample) |
| IL (1) | IL225876A0 (enExample) |
| MX (2) | MX385858B (enExample) |
| NZ (1) | NZ609501A (enExample) |
| PL (1) | PL2643019T3 (enExample) |
| PT (1) | PT2643019T (enExample) |
| RU (1) | RU2013123793A (enExample) |
| SG (1) | SG189982A1 (enExample) |
| WO (1) | WO2012071381A1 (enExample) |
| ZA (1) | ZA201302983B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013004776A2 (pt) * | 2010-08-27 | 2017-09-19 | Stem Centrx Inc | moduladores de proteína notum e métodos de uso |
| MX385858B (es) | 2010-11-24 | 2025-03-18 | Lexicon Pharmaceuticals Inc | Anticuerpos que se unen a notum pectinacetilesterasa. |
| DK2663579T3 (en) | 2011-01-14 | 2017-07-31 | Univ California | THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF |
| US8802365B2 (en) * | 2011-03-22 | 2014-08-12 | Whitehead Institute For Biomedical Research | Methods for identifying candidate modulators of NOTUM activity |
| JP6391574B2 (ja) * | 2012-08-31 | 2018-09-26 | アルゲン−エックス ビーブイビーエー | 種間標的内交差反応性を有する抗体分子を産生する方法 |
| CA2976926A1 (en) | 2015-02-19 | 2016-08-25 | Compugen Ltd. | Anti-pvrig antibodies and methods of use |
| WO2020150282A1 (en) * | 2019-01-18 | 2020-07-23 | Askgene Pharma Inc. | Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis |
| CN110317271B (zh) * | 2019-07-02 | 2021-04-30 | 武汉云克隆科技股份有限公司 | 一种pinp重组抗体的重/轻链可变区及编码基因和重组抗体 |
| AU2021400733A1 (en) * | 2020-12-16 | 2023-07-13 | Memorial Sloan Kettering Cancer Center | Cd40 binding molecules and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| ES2199935T3 (es) | 1991-03-15 | 2004-03-01 | Amgen Inc. | Pegilacion de polipeptidos. |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| TW313568B (enExample) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
| US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| US6080576A (en) | 1998-03-27 | 2000-06-27 | Lexicon Genetics Incorporated | Vectors for gene trapping and gene activation |
| GB0201808D0 (en) * | 2002-01-25 | 2002-03-13 | European Molecular Biology Lab Embl | Protein |
| US20040063924A1 (en) * | 2002-01-28 | 2004-04-01 | Y Tom Tang | Secreted proteins |
| EP1652923B1 (en) * | 2003-08-08 | 2011-10-12 | Perseus Proteomics Inc. | Gene overexpressed in cancer |
| BR112013004776A2 (pt) * | 2010-08-27 | 2017-09-19 | Stem Centrx Inc | moduladores de proteína notum e métodos de uso |
| MX385858B (es) | 2010-11-24 | 2025-03-18 | Lexicon Pharmaceuticals Inc | Anticuerpos que se unen a notum pectinacetilesterasa. |
-
2011
- 2011-11-22 MX MX2018001218A patent/MX385858B/es unknown
- 2011-11-22 NZ NZ609501A patent/NZ609501A/en not_active IP Right Cessation
- 2011-11-22 BR BR112013012858-5A patent/BR112013012858B1/pt not_active IP Right Cessation
- 2011-11-22 US US13/885,815 patent/US20130302346A1/en not_active Abandoned
- 2011-11-22 HU HUE11843652A patent/HUE043576T2/hu unknown
- 2011-11-22 KR KR1020187016214A patent/KR20180069083A/ko not_active Ceased
- 2011-11-22 EP EP11843652.6A patent/EP2643019B1/en not_active Not-in-force
- 2011-11-22 KR KR1020137013390A patent/KR20140026334A/ko not_active Ceased
- 2011-11-22 JP JP2013541012A patent/JP6033229B2/ja not_active Expired - Fee Related
- 2011-11-22 AU AU2011332007A patent/AU2011332007C1/en not_active Ceased
- 2011-11-22 WO PCT/US2011/061785 patent/WO2012071381A1/en not_active Ceased
- 2011-11-22 MX MX2013005906A patent/MX357166B/es active IP Right Grant
- 2011-11-22 RU RU2013123793/10A patent/RU2013123793A/ru not_active Application Discontinuation
- 2011-11-22 CA CA2817415A patent/CA2817415C/en active Active
- 2011-11-22 PL PL11843652T patent/PL2643019T3/pl unknown
- 2011-11-22 CN CN201180056452.6A patent/CN103298490B/zh not_active Expired - Fee Related
- 2011-11-22 SG SG2013031083A patent/SG189982A1/en unknown
- 2011-11-22 ES ES11843652T patent/ES2718849T3/es active Active
- 2011-11-22 PT PT11843652T patent/PT2643019T/pt unknown
- 2011-11-22 DK DK11843652.6T patent/DK2643019T3/en active
-
2013
- 2013-04-22 IL IL225876A patent/IL225876A0/en active IP Right Grant
- 2013-04-24 ZA ZA2013/02983A patent/ZA201302983B/en unknown
- 2013-06-24 CO CO13149527A patent/CO6721048A2/es not_active Application Discontinuation
-
2015
- 2015-11-25 US US14/952,264 patent/US20160152731A1/en not_active Abandoned
-
2019
- 2019-02-15 US US16/277,466 patent/US11059907B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ609501A (en) | Antibodies to notum pectinacetylesterase | |
| IN2012DN05237A (enExample) | ||
| TN2012000555A1 (en) | Antibodies to human gdf8 | |
| IL189788A0 (en) | Human monoclonal antibodies to cd70 | |
| PH12015500248A1 (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
| PH12013500933A1 (en) | Methods and compositions for neural disease immunotherapy | |
| IL184733A0 (en) | Human monoclonal antibodies to prostate specific membrane | |
| MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
| IL191340A (en) | Monoclonal antibodies against e8o | |
| EP2501800A4 (en) | HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN NUCLEOLIN | |
| WO2009128963A3 (en) | Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof | |
| TW200639182A (en) | Antibody variants and uses thereof | |
| MY157173A (en) | Modified humanised anti-interleukin-18 | |
| EP2566890A4 (en) | ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE | |
| UA107574C2 (ru) | Гуманизированное антитело, специфическое к протофибрилярной формы бета-амилоидного пептида | |
| PH12013501339A1 (en) | Anti-pcsk9 antibodies and methods of use | |
| SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
| ZA200802641B (en) | Human monoclonal antibodies to CD70 | |
| MX2013011012A (es) | Cristales de anticuerpos anti-esclerostina y formulaciones de los mismos. | |
| NZ601588A (en) | Methods for treating breast cancer | |
| ATE553778T1 (de) | Für humanes hepcidin spezifische antikörper | |
| SG160248A1 (en) | Use of novel monoclonal antibodies targeting human embryonic stem cells to characterize and kill induced pluripotent stem cells | |
| PH12013500616A1 (en) | Antibody compositions and methods of use | |
| MX2015002465A (es) | Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1). | |
| PH12013500432A1 (en) | Anti-vegfr-3 antibody compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 NOV 2016 BY CPA GLOBAL Effective date: 20151012 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 NOV 2017 BY CPA GLOBAL Effective date: 20161007 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 NOV 2018 BY CPA GLOBAL Effective date: 20171005 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 NOV 2019 BY CPA GLOBAL Effective date: 20181011 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 NOV 2020 BY CPA GLOBAL Effective date: 20191010 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 NOV 2021 BY CPA GLOBAL Effective date: 20201008 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 NOV 2022 BY CPA GLOBAL Effective date: 20211008 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 NOV 2023 BY CPA GLOBAL Effective date: 20221007 |
|
| LAPS | Patent lapsed |